]>

IRCT20190506043488N1 IRCT 2019-12-27 Zahedan University of Medical Sciences The effect of intravenous iron on fgf23 and iron profile The effect of injectable iron supplementation on FGF23 levels in hemodialysis patients 2019-09-23 anticipated 45 Complete https://irct.ir/trial/39302 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Diagnostic. 2 Iron deficiency anemia in hemodialysis patients. Intervention group: Hemodialysis patients who meet the inclusion criteria will receive 100 mg of intravenous iron (venoffer) supplement 10 times during 3 months after each dialysis.. Yes - There is a plan to make this available What will be shared: The whole potential data is unpublished after being unidentifiable When: Start the access period 6 months after printing the results To whom: Only available to scholars working in academic and academic institutions Conditions: Use of study data is permitted for any use by researchers working in academic and scientific institutions Where to obtain: Ali ebn Abitalib Hospital, Zahedan, Department of Hemodialysis Deputy of Research of Zahedan University of Medical Sciences, Faculty of Medicine Dr. Ali Alidadi, professor of the thesis, telephone number 09120621590 How to obtain: It takes about 1 month from the request of the applicant to access data files or time documentation Comments:

public Foroogh Asli

Sistan and Baluchestan University of Zahedan, University of Milan 5th University

Zahedan Iran (Islamic Republic of) 9816743111 +98 54 3329 5575 forooghasli1366@zaums.ac.ir Zahedan University of Medical Sciences scientific Foroogh Asli

Sistan and Baluchestan University of Zahedan, University of Milan 5th University

Zahedan Iran (Islamic Republic of) 9816743111 +98 54 3329 5575 forooghasli1366@zaums.ac.ir Zahedan University of Medical Sciences Iran (Islamic Republic of) All patients with hemodialysis who have completed their dialysis for at least 3 months. All patients with hemodialysis aged 18 to 70 years. All patients with hemodialysis have ferritin less than 200 and transferin saturation less than 20 %. 18 years 70 years Both Dissatisfaction patients to enter the study transfusion Malignancy Parathyroidectomy Infection of any type ( catheter infection, UTI,....) Recent consumption of corticosteroid Active bleeding Advanced heart disease liver disease N18.5 Chronic kidney disease, stage 5 Treatment - Drugs Intervention group: Hemodialysis patients who meet the inclusion criteria will receive 100 mg of intravenous iron (venoffer) supplement 10 times during 3 months after each dialysis. Fibroblast growth factor 23 level. Timepoint: Measurement of Fibroblast growth factor 23 level at the beginning of the study (before intervention) and 3 months after intervention. Method of measurement: Laboratory measurement. Deputy of Research and Technology of Zahedan University of Medical Science Approved 2019-09-21 Ethics committee of Zahedan University of Medical Sciences Sistan and Baluchestan Zahedan - Persian Gulf Highway - Imam Khomeini Mosque - Ali Bin Abi Talib Hospital Zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)